Dr. Mohd Danish Ansari is an academician and researcher specializing in pharmaceutics, pharmaceutical nanotechnology, and advanced drug delivery systems. He currently serves as a lecturer at the Dept. of Pharmaceutical Technology, Faculty of Pharmacy, University of Malaya, Kuala Lumpur, Malaysia. His teaching portfolio spans pharmaceutical engineering, industrial pharmacy, novel drug delivery systems, pharmaceutical analysis, regulatory affairs, and dosage form design at both undergraduate and postgraduate levels. He also holds several academic leadership roles, including Course Coordinator (Quality Assurance), Head of the Certification Unit, member of the Universiti Malaya Research Ethics Committee (UMREC), Accreditation Task Force member, and Final Year Project (FYP) Coordinator. He actively contributes as a postgraduate thesis evaluator, PhD examiner, and academic administrator.

Dr. Ansari earned his Ph.D. in Pharmaceutics from Jamia Hamdard, where his doctoral research focused on the development of novel vesicular spanlastic systems for enhancing the bioavailability of BCS Class II drugs via the transdermal route. He also completed his M.Pharm, B.Pharm, and D.Pharm from the same institution. His research interests include pharmaceutical nanotechnology, transdermal and targeted drug delivery, biomaterials, hydrogels, lipid and polymeric nanoparticles, nanomedicine, pharmacokinetics and pharmacodynamics, and regulatory sciences.

In addition to academia, Dr. Ansari has professional experience as an associate scientific writer at leading life sciences consulting organizations, where he contributed to manuscript preparation, regulatory writing, medical information development, instructional design, data analytics, and scientific communications. Earlier in his career, he served as a lecturer in pharmaceutics and worked as a project assistant under a DST Nano Mission-funded project of the government of India, focusing on the formulation and in vivo evaluation of nanoemulsion-based drug delivery systems for osteoporosis management.

Dr. Ansari is a GPAT-qualified professional and recipient of multiple Best Publication Awards for high-impact research contributions. His scholarly work reflects a strong commitment to innovation in nanomedicine and translational pharmaceutical research. Dr. Ansari has authored over 25 high-impact publications in Q1–Q3 journals, including pioneering work on nanospanlastics, lipid-polymer hybrid nanoparticles, SNEDDS, and nanoengineered delivery systems for neurological disorders, osteoporosis, and cancer. He has contributed book chapters on nanostructured drug carriers and fixed-dose combination techniques. His research has been recognized internationally, and he has presented at multiple conferences, receiving awards for oral presentations. His publications demonstrate a strong translational focus, bridging innovative nanotechnology with patient-centered therapeutic applications.

Dr. Ansari serves as a peer reviewer for several national and international journals. His expertise in pharmaceutics, nanotechnology, and drug delivery enables him to critically evaluate manuscripts and contribute to maintaining high scientific standards in these publications.